The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback